Insulin

Patients with type 2 diabetes uncontrolled by metformin who received pioglitazone and insulin demonstrated increased risk for ischemic heart disease, according to findings published in the Journal of Diabetes and Its Complications.

From 1990 to 2022, diabetes prevalence rose greatly, but for the most part, treatment did not increase at all or sufficiently, especially in low- and middle-income countries, researchers reported in The Lancet.

A novel duodenal mucosal renewal procedure followed by once-weekly semaglutide could allow adults with type 2 diabetes to maintain glycemic control without insulin therapy, according to a speaker.

The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.

In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

States that approved caps to limit out-of-pocket costs for insulin did not have increased uptake in insulin use among people with diabetes and commercial insurance, according to findings published in Health Affairs.

Researchers purchased prefilled semaglutide pens from six online vendors, of which three were nondelivery scams, according to findings from a research letter published in JAMA Network Open.